Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy

Clinical & Experimental Metastasis, Apr 2013

Colorectal carcinoma is, through to its high rate of liver metastasis (mCRC), the second most cause of cancer death worldwide. Tumor resection represents the only potential cure. In cases of unresectable disease systemic chemotherapy (sCHT) remains the therapy of choice. Modern sCHT regimens including biological agents can induce tumor response that leads to curative surgery of initially unresectable mCRC. However, liver-directed therapy via hepatic arterial infusion (HAI) may produce higher response rates than sCHT. Herein we studied whether a HAI of cetuximab (CE) plus bevacizumab (BE) with or without oxaliplatin (OX) can inhibit tumor growth in a rat model. WAG/Rij rats underwent subcapsular hepatic tumor implantation. After 10 days animals received either HAI or sCHT of CE plus BE, OX or all three drugs. Saline-treated animals served as controls. Tumor growth was estimated at day 10 and 13. On day 13 liver and tumor tissue was studied histologically and immunohistochemically. In controls the tumors grew about 50 %. OX alone was not capable of inhibiting tumor growth. In contrast, CE plus BE given as HAI significantly reduced tumor growth compared to sCHT (p < 0.05). HAI of CE plus BE combined with OX yielded an even more pronounced inhibition of tumor growth. Immunohistochemistry revealed a decreased tumor cell proliferation and tumor vascularization. The present study demonstrates that HAI of CE plus BE is effective to inhibit tumor growth. This effect is even more pronounced in combination with OX. Systemic application of these agents cannot achieve comparable effects.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://link.springer.com/content/pdf/10.1007%2Fs10585-012-9550-9.pdf

Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy

Jens Sperling 0 1 2 David Brandhorst 0 1 2 Thilo Schafer 0 1 2 Christian Ziemann 0 1 2 Anna Benz-Weier 0 1 2 Claudia Scheuer 0 1 2 Otto Kollmar 0 1 2 Martin K. Schilling 0 1 2 Michael D. Menger 0 1 2 0 D. Brandhorst A. Benz-Weier C. Scheuer M. D. Menger Institute for Clinical and Experimental Surgery, University of Saarland , Homburg/Saar, Germany 1 Present Address: J. Sperling (&) Department of General and Visceral Surgery, University Medical Center, Georg August University Gottingen , Robert-Koch-Strasse 40, 37075 Gottingen, Germany 2 J. Sperling T. Schafer C. Ziemann O. Kollmar M. K. Schilling Department of General , Visceral, Vascular and Pediatric Surgery, Saarland University Hospital , Homburg/Saar, Germany Colorectal carcinoma is, through to its high rate of liver metastasis (mCRC), the second most cause of cancer death worldwide. Tumor resection represents the only potential cure. In cases of unresectable disease systemic chemotherapy (sCHT) remains the therapy of choice. Modern sCHT regimens including biological agents can induce tumor response that leads to curative surgery of initially unresectable mCRC. However, liver-directed therapy via hepatic arterial infusion (HAI) may produce higher response rates than sCHT. Herein we studied whether a HAI of cetuximab (CE) plus bevacizumab (BE) with or without oxaliplatin (OX) can inhibit tumor growth in a rat model. WAG/Rij rats underwent subcapsular hepatic tumor implantation. After 10 days animals received either HAI or sCHT of CE plus BE, OX or all three drugs. Salinetreated animals served as controls. Tumor growth was estimated at day 10 and 13. On day 13 liver and tumor tissue was studied histologically and immunohistochemically. In controls the tumors grew about 50 %. OX alone was not capable of inhibiting tumor growth. In contrast, CE plus BE given as HAI significantly reduced tumor growth compared to sCHT (p 0.05). HAI of CE plus BE combined with OX yielded an even more pronounced inhibition of tumor growth. Immunohistochemistry revealed a decreased tumor cell proliferation and tumor vascularization. The present study demonstrates that HAI of CE plus BE is effective to inhibit tumor growth. This effect is even more pronounced in combination with OX. Systemic application of these agents cannot achieve comparable effects. - Colorectal carcinoma has a rising incidence and is the second most cause of cancer related death worldwide [1, 2]. About 50 % of patients develop metastatic disease, whereby the liver remains the most common site of metastasis. These patients have a poor prognosis demonstrated by a 5-year survival rate in the range of 58 %. The only potential cure is complete resection of the hepatic tumor burden [3]. Unfortunately, a great number of patients suffer from unresectable disease. In these patients the main goal is to induce tumor response by systemic chemotherapy which can lead to curative surgery of initially unresectable metastases. During the last years, the development of new cytotoxic drugs and regimens as well as biological targeted agents like cetuximab (CE) or bevacizumab (BE) has improved the survival outcome of patients with unresectable disease [3]. Cetuximab is a monoclonal antibody directed against the ligand binding domain of the epidermal growth factor receptor (EGF-R). Bevacizumab is a monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The use of these antibodies in modern sCHT regimens has improved the 2-year survival rate, however, it still does not exceed 40 %. Of interest, the analysis of the 5-year survival rate could not show a benefit of the survival outcome [3, 4]. It is well known that liver-directed chemotherapy, which is achieved by hepatic arterial infusion, yields reproducibly higher response rates compared to sCHT both in preclinical and clinical settings [2, 5]. However, the overall value of HAI remains unclear [6]. Therefore, it has been suggested to evaluate the effect of a HAI especially with the delivery of novel cancer agents or drug combinations in further studies [7]. Accordingly, we herein studied whether a HAI of cetuximab plus bevacizumab (CE ? BE) alone or in combination with oxaliplatin (OX) is more effective than sCHT to inhibit tumor growth in a mCRC model of the rat liver. Materials and methods For the experiments we used 48 male WAG/Rij rats with a body weight of 248.3 5.5 g (mean standard error of the mean (SEM)). Animals were kept in a temperature- and humidity-controlled 12 h light/dark cycle environment with free access to water and standard laboratory chow (Altromin, Lage, Germany). Experimental protocol All experiments were approved by the local governmental ethic committee. Animals were randomized to eight groups (n = 6 each), whereby four groups of animals underwent HAI and four groups underwent sCHT. 10 days after tumor cell implantation relaparotomy was performed and animals received either (CE ? BE), (OX) or all three drugs (CE ? BE (...truncated)


This is a preview of a remote PDF: https://link.springer.com/content/pdf/10.1007%2Fs10585-012-9550-9.pdf

Jens Sperling, David Brandhorst, Thilo Schäfer, Christian Ziemann, Anna Benz-Weißer, Claudia Scheuer, Otto Kollmar, Martin K. Schilling, Michael D. Menger. Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy, Clinical & Experimental Metastasis, 2013, pp. 447-455, Volume 30, Issue 4, DOI: 10.1007/s10585-012-9550-9